Hepatitis C News

The Trump administration’s selection of longtime AIDS researcher Robert R. Redfield, MD, to be the next CDC director drew mixed reactions from experts and officials, including some who question his conduct on a research project several decades ago.

Researchers have developed a predictive score that quantifies the potential benefits of direct-acting antiviral therapy for patients with hepatitis C and decompensated cirrhosis, according to recently published data.

A program granting prison inmates with hepatitis C virus infection unrestricted access to direct-acting antiviral therapy nearly eliminated the virus at a correctional facility in Australia less than 2 years after its implementation, according to study findings published in Clinical Infectious Diseases.

Hepatitis C treatment with Mavyret for 8 weeks had an overall sustained virologic response rate of 98% regardless of baseline patient or viral characteristics in a cohort of patients with genotypes 1 through 6, according to a recently published study.

To address the underlying opioid addiction that so often leads to injection-related infections, experts have suggested that directly treating the addiction should be a priority for ID specialists. We asked Peter Chin-Hong, MD, a professor of medicine at the University of California, San Francisco School of Medicine and Infectious Disease News Editorial Board member, if he agrees that ID specialists should treat opioid use disorder with medicine.

The opioid epidemic in the United States has affected millions, exposing them to health risks that include a range of infectious diseases.

A new hepatitis C virus finger-stick test can be used to diagnose infection in a single clinical visit, delivering results in 1 hour, according to researchers.

Recently published data showed that treatment outcomes did not differ between 8 weeks and 12 weeks of Harvoni among black patients with hepatitis C, contrary to guideline recommendations.

BOSTON — The vast majority of patients with HIV do not spontaneously clear acute hepatitis C virus, according to research presented at the Conference on Retroviruses and Opportunistic Infections.

Recently published data showed no association between direct-acting antiviral therapy and an increased risk for hepatocellular carcinoma recurrence among liver transplantation candidates with hepatitis C who experienced initial complete response to local-regional therapy.